HDL vagy non-HDL

az itt a kérdés. A residualis dyslipidaemia gyógyszeres kezelésének lehetoségei

Translated title of the contribution: HDL, or non-HDL: That is the question. Possibilities of pharmacological treatment in residual dyslipidaemia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Instead of LDL-cholesterol, non-HDL-cholesterol is proposed as a secondary lipid target when triglyceride level is above 2.3 mmol/L. Non-HDL-cholesterol target values are 0.8 mmol/L higher than those for LDL-cholesterol in the same cardiovascular risk category. Currently, the main issue of lipidology is the degree by which the cardiovascular risk can be reduced with the treatment of residual dyslipidemia that exists under statin therapy. In such a role the examined agents have essentially failed despite their more or less profound effect on HDL-cholesterol and/or non-HDL-cholesterol. The largest loser has been the nicotinic acid. The results of cardiovascular, otherwise controversial fish oil studies cannot be considered convincing because of the administered low doses. In a combination with statin (i) ezetimibe may have role if the LDL-cholesterol target cannot be reached with statin monotherapy, or (ii) fibrates, in case of large increase of triglyceride level, or in less severe hypertriglyceridemia if it is associated with considerable decrease in HDL-cholesterol level. Potential further possibilities are: (i) cholesterol ester transfer protein inhibitors that dramatically raise HDL-cholesterol, while reduce LDL-cholesterol, or (ii) proprotein convertase subtilisin/kexin 9 inhibitors that markedly decrease LDL-cholesterol even on the top of statin.

Original languageHungarian
Pages (from-to)62-68
Number of pages7
JournalOrvosi Hetilap
Volume155
Issue number2
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
LDL Cholesterol
Pharmacology
HDL Cholesterol
Cholesterol
Triglycerides
Proprotein Convertases
Cholesterol Ester Transfer Proteins
Fibric Acids
Subtilisin
Fish Oils
Hypertriglyceridemia
Niacin
Lipids
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HDL vagy non-HDL : az itt a kérdés. A residualis dyslipidaemia gyógyszeres kezelésének lehetoségei. / Bajnok, L.

In: Orvosi Hetilap, Vol. 155, No. 2, 01.01.2014, p. 62-68.

Research output: Contribution to journalArticle

@article{ba1d4c2728a7429f85ded44ac5d56891,
title = "HDL vagy non-HDL: az itt a k{\'e}rd{\'e}s. A residualis dyslipidaemia gy{\'o}gyszeres kezel{\'e}s{\'e}nek lehetos{\'e}gei",
abstract = "Instead of LDL-cholesterol, non-HDL-cholesterol is proposed as a secondary lipid target when triglyceride level is above 2.3 mmol/L. Non-HDL-cholesterol target values are 0.8 mmol/L higher than those for LDL-cholesterol in the same cardiovascular risk category. Currently, the main issue of lipidology is the degree by which the cardiovascular risk can be reduced with the treatment of residual dyslipidemia that exists under statin therapy. In such a role the examined agents have essentially failed despite their more or less profound effect on HDL-cholesterol and/or non-HDL-cholesterol. The largest loser has been the nicotinic acid. The results of cardiovascular, otherwise controversial fish oil studies cannot be considered convincing because of the administered low doses. In a combination with statin (i) ezetimibe may have role if the LDL-cholesterol target cannot be reached with statin monotherapy, or (ii) fibrates, in case of large increase of triglyceride level, or in less severe hypertriglyceridemia if it is associated with considerable decrease in HDL-cholesterol level. Potential further possibilities are: (i) cholesterol ester transfer protein inhibitors that dramatically raise HDL-cholesterol, while reduce LDL-cholesterol, or (ii) proprotein convertase subtilisin/kexin 9 inhibitors that markedly decrease LDL-cholesterol even on the top of statin.",
keywords = "fibrate, HDL-C, lipid target values, non-HDL-C, statin",
author = "L. Bajnok",
year = "2014",
month = "1",
day = "1",
doi = "10.1556/OH.2014.29797",
language = "Hungarian",
volume = "155",
pages = "62--68",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - HDL vagy non-HDL

T2 - az itt a kérdés. A residualis dyslipidaemia gyógyszeres kezelésének lehetoségei

AU - Bajnok, L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Instead of LDL-cholesterol, non-HDL-cholesterol is proposed as a secondary lipid target when triglyceride level is above 2.3 mmol/L. Non-HDL-cholesterol target values are 0.8 mmol/L higher than those for LDL-cholesterol in the same cardiovascular risk category. Currently, the main issue of lipidology is the degree by which the cardiovascular risk can be reduced with the treatment of residual dyslipidemia that exists under statin therapy. In such a role the examined agents have essentially failed despite their more or less profound effect on HDL-cholesterol and/or non-HDL-cholesterol. The largest loser has been the nicotinic acid. The results of cardiovascular, otherwise controversial fish oil studies cannot be considered convincing because of the administered low doses. In a combination with statin (i) ezetimibe may have role if the LDL-cholesterol target cannot be reached with statin monotherapy, or (ii) fibrates, in case of large increase of triglyceride level, or in less severe hypertriglyceridemia if it is associated with considerable decrease in HDL-cholesterol level. Potential further possibilities are: (i) cholesterol ester transfer protein inhibitors that dramatically raise HDL-cholesterol, while reduce LDL-cholesterol, or (ii) proprotein convertase subtilisin/kexin 9 inhibitors that markedly decrease LDL-cholesterol even on the top of statin.

AB - Instead of LDL-cholesterol, non-HDL-cholesterol is proposed as a secondary lipid target when triglyceride level is above 2.3 mmol/L. Non-HDL-cholesterol target values are 0.8 mmol/L higher than those for LDL-cholesterol in the same cardiovascular risk category. Currently, the main issue of lipidology is the degree by which the cardiovascular risk can be reduced with the treatment of residual dyslipidemia that exists under statin therapy. In such a role the examined agents have essentially failed despite their more or less profound effect on HDL-cholesterol and/or non-HDL-cholesterol. The largest loser has been the nicotinic acid. The results of cardiovascular, otherwise controversial fish oil studies cannot be considered convincing because of the administered low doses. In a combination with statin (i) ezetimibe may have role if the LDL-cholesterol target cannot be reached with statin monotherapy, or (ii) fibrates, in case of large increase of triglyceride level, or in less severe hypertriglyceridemia if it is associated with considerable decrease in HDL-cholesterol level. Potential further possibilities are: (i) cholesterol ester transfer protein inhibitors that dramatically raise HDL-cholesterol, while reduce LDL-cholesterol, or (ii) proprotein convertase subtilisin/kexin 9 inhibitors that markedly decrease LDL-cholesterol even on the top of statin.

KW - fibrate

KW - HDL-C

KW - lipid target values

KW - non-HDL-C

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=84891866930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891866930&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29797

DO - 10.1556/OH.2014.29797

M3 - Article

VL - 155

SP - 62

EP - 68

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 2

ER -